|
1. BIOLOGIE
|
|
|
‘Jumping genes’ drive many cancers [WUSTL]
|
|
|
|
|
|
Wang and his colleagues found that many cancers that get switched into overdrive and boost tumor growth have jumping genes that function as a kind of stealthy “on switch.” These cryptic switches can force a gene to be turned on all the time, even though it should be off.
|
|
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
4.12 BIOPSIES LIQUIDES
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
Mopping Up Excess Chemotherapy Drugs [The Scientist]
|
|
|
|
|
|
Proof-of-principle tests showed that when placed in the iliac vein in the lower abdomen of live pigs, the device effectively captured more than two-thirds of the doxorubicin infused a short distance upstream.
|
|
|
|
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
5.12 IMMUNOTHÉRAPIES
|
|
|
|
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
|
|
|
|
5.2.1 PHARMA - PARTENARIATS
|
|
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
Revlimid [EMA]
|
|
|
|
|
|
Revlimid as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.
|
|
|
|
|
|
|
5.9.4 AACR - POUMON
|
|
|
|
|
|
5.9.5 AACR - CAR-T
|
|
|
|
|
|
5.9.7 AACR - DIVERS
|
|
|
|
5.9.9 AACR - IMMUNOTHÉRAPIES
|
|
|
|
|
|
|
|
6.1 OBSERVATION
|
|
|
Asbestos exposure putting lives at risk 20 years since ban [IOSH]
|
|
|
|
|
|
While it takes 20 years or more for exposure to lead to a cancer diagnosis, the Institution of Occupational Safety and Health (IOSH) is concerned that the number of buildings containing asbestos and a widespread lack of awareness and uncertainty on how to manage it – particularly among small and medium-sized organisations – means people will continue to become seriously ill in decades to come.
|
|
|
|
|
|
|
|
6.6 PUBLICATIONS
|
|
|
|
|